Drug Bulletin - November 2004
Help on accessing alternative formats, such
as PDF, MP3 and WAV files, can be obtained in the alternate
format help section.
(90.7 KB)
The Non-Insured Health Benefits (NIHB) Program
provides supplementary
health benefits, including prescription and non-prescription drugs,
for
registered Indians, and recognized Inuit and Innu throughout Canada.
Open Benefits
(Effective October 1, 2004)
1. Brimonidine tartrate/timolol maleate, Ophthalmic Solution,
0.2% & 0.5% (Combigan® - Allergan Inc.)
Combigan® is indicated for the control of intraocular hypertension
in patients with chronic open-angle glaucoma or ocular hypertension.
2.Almotriptan malate, Tablet, 6.25mg and 12.5mg (Axert
- Janssen-Ortho Inc.)
Axert® is indicated for the acute treatment of migraine with
or without aura in adults
3. Risperidone orally disintegrating, Tablet, 0.5mg, 1mg
and 2mg (Risperdal-M - Janssen-Ortho Inc.)
Risperdal-M is indicated for the acute treatment and maintenance
treatment of schizophrenia and related psychotic disorders.
New Limited Use Benefits (Prior approval required)
(Effective January 1, 2005)
1.Ezetimibe, Tablet, 10mg (EzetrolTM - Merck Frosst/Schering
Pharmaceuticals)
EzetrolTM will be a limited use benefit for the treatment of primary
hypercholesterolemia either alone or in combination with a "statin".
A. For use in combination with a HMG-CoA reductase inhibitor ('statin')
in patients with hypercholesterolemia who have not reached target
LDL levels despite the use of maximally tolerated "statin" doses.
B. For use as monotherapy in the management of hypercholesterolemia
in patients intolerent to HMG-CoA reductase inhibitors.
2. . Levetiracetam, Tablet, 250mg, 500mg and 750mg (Keppra® -
UCB Pharma Inc [Lindbeck Canada - distributor])
Keppra® will be a limited use benefit for adjunctive therapy in
the management of patients with epilepsy not controlled with conventional
therapy.
For use in combination with other anti-epileptic medication(s)
in the treatment of partial seizures in patients who are refactory
to adequate trials of three anti-epileptic medications used either
as monotherapy or in combination. This product must be prescribed
by a Neurologist.
3.Atazanavir sulfate, Capsule, 150mg and 200mg (ReyatazTM
- Bristol-Myers Squibb Canada)
ReyatazTM will be a limited use benefit for the treatment of HIV-1
infection in antiretroviral-naïve and antiretroviral treatment-experienced
patients.
For the management of HIV in patients who failed other protease
inhibitor combinations, or for patients who experienced a lack
of tolerability to other protease inhibitors.
New Indications Added to Existing Limited Use Benefits
The following drugs will not be added to the NIHB Drug Benefit
List:
1.Salmeterol xinafoate/fluticasone propionate, Powder
for Inhalation, 50mcg & 250mcg and 50mcg & 500mcg (Advair
Diskus® - GlaxoSmithKline)
(a) For the treatment of moderate** to severe** COPD, if a patient
continues to be symptomatic after an adequate trial (2-4 months)
of ipatroprium at a dose of 4 puffs four times daily and short-acting
beta 2-agonists (indicating poor control).
By Symptom/Disability:
Moderate: shortness of breath from COPD causing the patient to
stop after walking approximately 100 meters (or after a few minutes)
on the level.
Severe: shortness of breath from COPD resulting in the patient
being too breathless to leave the house or breathless after undressing,
or the presence of chronic respiratory failure or clinical signs
of right heart failure.
**Canadian Thoracic Society COPD classification
2.Imatinib mesylate, Capsule, 100mg (GleevecTM - Novartis)
The following new indication will be added to the existing criteria:
(a) For newly diagnosed adult patients with Philadelphia chromosome-positive
chronic myeloid leukemia (CML)
NIHB decision not to add the following drug products to the NIHB Drug Benefit List after review by the Federal Pharmacy and Therapeutics Committee
1. Telithromycin, Tablet, 400mg (KetekTM - Aventis
Pharma Inc.)
2. Peginterferon alfa-2a, Solution, 180mcg/mL and 180mcg/
0.5mL (Pegasys® - Hoffman-LaRoche Limited)
3. Gefitinib, Tablet, 250mg (Iressa - AstraZeneca
Canada Inc.)
4. Mirtazapine, Rapid Dissolving Tablet, 15mg, 30mg and
45mg (Remeron RD - Organon Canada Ltd.)
5. Norelgestromin/ethinyl estradiol, Transdermal Patch,
6mg & 0.60mg (Evra - Janssen-Ortho Inc.)
NIHB Deferred Decision on Listing
1. Enfuvirtide, Powder for Solution, 108mg/Vial (Fuzeon® -
Hoffman La Roche Limited)
2. Etanercept, Injection, 25mg/mL (Enbrel® -New
Indications)
3. Methylphenidate hydrochloride, Extended-Release Tablet,
18mg, 36mg and 54mg (Concerta®)
4. Perindopril erbumine/indapamide, Tablet, 2mg & 0.625mg (Preterax®)
Changes in Benefit Status
(Effective January 1, 2005 )
Carvedilol, Tablet, 3.125mg, 6.25mg, 12.5mg and 25mg (Coreg® -
GlaxoSmithKline and Generics) will change status from an exception
to a limited use benefit, effective January 1, 2005 . The criteria
for use will be as follows:
a) For patients with systolic heart failure of ischemic or non-ischemic
origin, with or without digoxin, PLUS
b) Concurrent treatment with diuretics and angiotension converting
enzyme inhibitors or angiotension receptor blockers, unless contraindicated.
Benefits Delisted from the NIHB Drug Benefit List:
As a result of Merck Frosst Canada & Co. announcement of their
voluntary worldwide withdrawal of Vioxx ® (rofecoxib) from
the market, Vioxx® has been delisted as a benefit under the
NIHB Program, effective September 30th, 2004 .
Expanding Maximum Allowable Quantities for Narcotic Combination Products
Currently, the NIHB Program has a quantity limitation for products
containing codeine 30mg in combination with either acetaminophen
or acetylsalicylic acid and with or without caffeine. A total of
1080 tablets is allowed in a 90-day period. All paid claims for
any codeine 30mg combination analgesic product are counted towards
the maximum allowable quantity.
Utilization patterns of other narcotic products were closely monitored
following implementation of maximum allowable quantities for the
codeine-containing analgesics. Effective January 1, 2005 , the
NIHB Program will be expanding the maximum allowable quantities
to include other narcotic combination products containing codeine
15mg and 60mg in combination with either acetaminophen or acetylsalicylic
acid and with or without caffeine. As well, maximum allowable quantities
will be applied to products containing oxycodone with either acetaminophen
or acetylsalicylic acid. A total of 1200 tablets will be allowed
in a 100-day period. All paid claims for these narcotic combination
products will be counted towards the maximum allowable quantity.
Emergency Supply Policy
Recent analysis of NIHB claims has shown what appears to be systematic
use of the Program's emergency supply policy. Providers are therefore
reminded that when a drug requiring prior approval is needed on
an emergency basis, and access to the NIHB Drug Exception Centre
is not possible (e.g. statutory holidays and after hours of operation
only), a pharmacist may dispense an initial course of treatment
(maximum of four days supply). It is important that the pharmacist
contact the NIHB Drug Exception Centre as soon as possible for
an approval to be backdated to cover the emergency supply. This
approval number must be included when submitting the four day emergency
supply claim. Additional dispensing of the balance of the prescription
must follow the usual prior approval process.
If a prior approval is granted, the pharmacist is provided with
a prior approval number and the details of the approved benefit
by fax. The prior approval number must be included on any subsequent
claim submitted for the requested approved drug benefit.
Claims submitted to the Program as emergency supply within the
hours of operation of the NIHB Drug Exception Centre will be subject
to audit.
NIHB Drug Use Evaluation Advisory Committee
In December 2003, the NIHB Program created a Drug Use Evaluation
Advisory Committee (DUEAC). The purpose of the DUEAC is to provide
recommendations to the NIHB Program to promote improvement in the
health outcomes of First Nations and Inuit clients through effective
use of pharmaceuticals. The Drug Use Evaluation (DUE) Program will
be developed within the context of First Nations and Inuit holistic
health views encompassing the determinants of health.
The DUE Program will aim to foster relationships and engage First
Nations and Inuit communities and health care professionals in
optimizing drug use.
Specific drug utilization reviews are recommended to the NIHB
Program and the results subsequently interpreted by the DUEAC.
The Committee is an independent advisory body of licensed health
care professionals - experts in drug use evaluation, Aboriginal
health issues and drug utilization. Criteria used by the Committee
will be consistent with standard, accepted references, sources
of drug information or peer-reviewed literature. All analytical
work will be conducted on an anonymized dataset to ensure individual
client's privacy is respected.
The majority of DUE Advisory Committee efforts will be focused
on initiatives that change broad practices, and thus impact health
outcomes of the entire client population. The NIHB Program will
introduce a new DUE Bulletin in the near future to provide information
to prescribers and pharmacy providers on the findings and recommendations
of the DUEAC. The first of these Bulletins will highlight the results
of an analysis of diabetic claimants within the NIHB Program.
Important Drug Safety Information
The following is taken from the Therapeutic Products Directorate
Web site:
Health Canada has recently issued warnings for SSRIs and other
recent anti-depressants regarding the potential for behavioural
and emotional changes, including risk of self harm.
For further information and for other Health Canada Advisories,
please visit the Health Canada Web site at:
www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/index_advisories_e.html
New Chemical Entity Drugs Under Review by the Common Drug Review
As of September 1, 2003 , submissions for new chemical entities
and new combination drug products are reviewed by the Common Drug
Review (CDR) at the Canadian Coordinating Office of Health Technology
Assessment (CCOHTA). The NIHB Program and other federal, provincial
and territorial drug plans make listing decisions based on the
Canadian Expert Drug Advisory Committee (CEDAC) recommendations
and other specific relevant factors, such as mandate, priorities
and resources.
For a list of drugs currently being reviewed through the Common
Drug Review (CDR) process, please refer to the Canadian Coordinating
Office of Health Technology Assessment (CCOHTA) website at:
www.ccohta.ca
November 2004 Report of the Auditor General of Canada to the House of Commons
Chapter 4 -- Management of Federal Drug Benefit Programs.
Drug benefit programs are one of the fastest growing areas of
federal spending on health. Between 2000--01 and 2002--03, spending
grew from $350 million to $438 million, a 25 percent increase in
just two years. The chapter looks at the drug benefit programs
of Health Canada (benefits for First Nations and Inuit), Veterans
Affairs Canada (veterans), National Defence (Canadian Forces members),
the Royal Canadian Mounted Police (force members), Citizenship
and Immigration Canada (certain designated classes of migrants),
and Correctional Service Canada (inmates of federal penitentiaries
and some former inmates on parole). The NIHB Program will be responding
to the findings of the audit when they are published.
For additional information please visit the Office of the Auditor
General of Canada Web Site at:
www.oag-bvg.gc.ca
|